Splicing Factor 3b Subunit 6 Is A Potential Drug Target Or Biomarker for Various Diseases

Target Name: SF3B6

NCBI ID: G51639

SF3B6

Splicing Factor 3b Subunit 6 Is A Potential Drug Target Or Biomarker for Various Diseases

Splicing factor 3b subunit 6 (SF3B6) is a protein that plays a critical role in the process of gene splicing, which is the process by which the instructions in the DNA are turned into the proteins that make up the cell. SF3B6 is a key regulator of splicing and has been identified as a potential drug target or biomarker for a variety of diseases.

SF3B6 is a protein that is expressed in a variety of tissues throughout the body, including the brain, heart, and kidneys. It is a member of the SF3B6 family, which includes a number of similar proteins that share a conserved catalytic core. The SF3B6 protein has a molecular weight of approximately 49 kDa and a pre-fusion cleavage site at amino acid residue 19.

SF3B6 is involved in the process of splicing by promoting the fidelity of the splicing machinery. Splicing is a critical process for the production of functional proteins from the DNA code. There are four main types of splicing: intronic splicing, exonic splicing, skipped exon splicing, and exonic-intronic splicing. Each type of splicing is responsible for producing a specific type of protein from the DNA code.

SF3B6 plays a key role in regulating the quality of spliced proteins. It is known to interact with the protein splicedexome, which is a complex that includes a variety of proteins that help to ensure the accuracy and stability of the spliced protein. SF3B6 is also known to interact with the protein Prm1, which is a key component of the splicing machinery.

SF3B6 has been identified as a potential drug target or biomarker for a variety of diseases. For example, studies have suggested that SF3B6 may be a potential therapeutic target for conditions such as cancer, neurodegenerative diseases, and autoimmune disorders.

One reason why SF3B6 may be a promising drug target is that it is involved in a number of important biological processes that are affected by the passage of time. For example, the levels of SF3B6 have been shown to decline with age, which may be a sign that the splicing machinery is less effective in producing the proteins that are needed to maintain the health and function of the cell. This may be a potential target for drugs that are designed to promote splicing and protect against age-related decline.

In addition to its potential therapeutic applications, SF3B6 is also a valuable biomarker for a variety of diseases. For example, studies have shown that the levels of SF3B6 are often reduced in the brains of individuals with neurodegenerative diseases, which may be a sign that these diseases are caused by problems with splicing. In addition, SF3B6 has been shown to be involved in the development and progression of certain cancers, which may make it an attractive target for cancer therapies.

Overall, SF3B6 is a protein that plays a critical role in the process of gene splicing and has been identified as a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of SF3B6 in these processes and to develop effective treatments for the diseases that are caused by problems with splicing.

Protein Name: Splicing Factor 3b Subunit 6

Functions: Involved in pre-mRNA splicing as a component of the splicing factor SF3B complex (PubMed:27720643). SF3B complex is required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence (BPS) in pre-mRNA (PubMed:12234937). Directly contacts the pre-mRNA branch site adenosine for the first catalytic step of splicing (PubMed:16432215). Enters the spliceosome and associates with the pre-mRNA branch site as part of the 17S U2 or, in the case of the minor spliceosome, as part of the 18S U11/U12 snRNP complex, and thus may facilitate the interaction of these snRNP with the branch sites of U2 and U12 respectively (PubMed:16432215)

The "SF3B6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SF3B6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets